Overview

Nimotuzumab,Camrelizumab, and Neoadjuvant ChemotherapynCT in the Treatment of Esophageal Squamous Cell Carcinoma

Status:
ENROLLING_BY_INVITATION

Trial end date:
2027-11-01

Target enrollment:

Participant gender:

Summary

We plan to conduct a single-center,prospective, Open Label, Randomized Controlled, Phase II Clinical Study of the Combination of Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy in the Treatment of Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Phase:

PHASE2

Details

Lead Sponsor:

Peking University

Treatments:

camrelizumab
Cisplatin
nimotuzumab